Эффективность и безопасность различной комбинированной сахароснижающей терапии в лечении больных сахарным диабетом 2 типа
Диссертация
Автором лично были выполнены все этапы работы: отбор больных СД 2 типа для исследования, последующее амбулаторное наблюдение с контролем гликемии, уровня HbAlc на аппарате DCA 2000+ («BayerHealthcare», Германия) и коррекцией сахароснижающей терапии, а также анализ и статистическая обработка полученных при исследовании данных. Проведенный автором анализ полученных результатов позволил сделать… Читать ещё >
Список литературы
- Адашева Т.В., Демичева О. Ю. Метаболический синдром основы патогенетической терапии // Лечащий врач. — 2003. -№ 10. -С.24−28.
- Аметов A.C., Карпова Е. В. Особенности комбинированной терапии сахарного диабета типа 2 у пациентов с преобладанием инсулинорезистентности // Фарматека. 2008. -№ 17. — С. 14−20.
- Балаболкин М.И., Креминская В. М., Клебанова Е. М. Бигуаниды: антигипергликемическое и вазопротективное действия // Consilium Medicum. 2003. — Т.5. -№ 9. — С.487−491.
- Борушнова О.В., Гельцер Б. И., Морозова A.M. Коррекция нарушений углеводного и липидного обмена у больных метаболическим синдромом // Российский национальный конгресс «Человек и лекарство 9-ый». Тезисы докладов. — М., 2002. — С.65.
- Бутрова С. А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению // Рус. мед. журн. 2001.- № 2.- С.56−60.
- Дедов И.И. Сахарный диабет в Российской Федерации: проблемы и пути решения // Сахарный диабет. -1998.-№ 1.-С. 7−18.
- Дедов И.И., Демидова И. Ю. Основные принципы терапии сахарного диабета 2 типа // Сахарный диабет. 1999. — № 1.- С. 23−27.
- Дедов И.И., Демидова И. Ю. Бигуаниды в современной практике лечения сахарного диабета 2 типа // Пособие для врачей. — 1999.- М.: Берлин-Хеми/Группа Менарини, 2001. 40 с.
- Дедов И.И., Шестакова М. В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом: Пособие для врачей. -М. Медицина, 2006. 94 с.
- Демидова И.Ю. Лечение сахарного диабета 2 типа// Фарматека. -2002.-№ 5.-С.3−8.
- Мычка В.Б., Чазова И. Е. Сердечно-сосудистые осложнения сахарного диабета 2 типа // Consilium medicum. 2003. — Т. 5. — № 9. — С. 504- 509.
- Основы клинической фармакологии и рациональной фармакотерапии. Руководство для практикующих врачей/ Под общей редакцией Ю. Б. Белоусова, МБ. Леоновой. М. Бионика, 2002 — с. 368.
- Отраслевой стандарт 'Юшнико-экономические исследования. Общие положения."// Журн. Проблемы стандартизации в здравоохранении.-2002.-№ 5- с.55−67.
- Старостина Е.Г. Бигуаниды: второе рождение// Новый медицинский журнал.-1998.-№ 1-С.З-8.
- Экономическая оценка эффективности лекарственной терапии (фармакоэкономический анализ)/ Под редакцией П. А. Воробьева. М.: Ньюдиамед, 2000. — 80 с.
- Физиология человека/ Под редакцией Р. Шмидта и Г. Тевса: Пер. с англ.- М.:МИР, 1996.-406 с.
- Althoff Р.Н., Haupt Е., Pichel С. Metformin increases insulin sensitivity and first phase of the arginin induced insulin response in type 2 diabetes// Diabetes. -1991.- vol.40. — Suppl. 1. — P.342.
- American Diabetes Association Standards of Medical Care in Diabetes. Standards of Medical Care in Diabetes// Diabetes Care. -2008. -2008.-№ 31 (Suppl. 1).-P. 13−54.
- Anderson D.K.G., Svardsud D. Long-term glycemic control relates to mortality in type II diabetes// Diabetes Care. -1995. vol.18 -P.1543−43.
- Anderson J.W., Kendall C.W., Jenkins D.J. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies // J Am Coll Nutr. -2003. № 22. — P.331−339.
- Arafat T. Kaddoumi A., Shami M. Pharmacokinetics and pharmocodynamics of two oral formulations of metformin hydrochloride// Adv. Ther. 1994 — vol. II. — P. 21- 23.
- Argaud D., Roth H., Wiemspreger N. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes // Eur.J. Biochem. 1993. -vol.213. -P. 1341−8.
- Aviles-Santa L., Sinding J., Raskin P. Effects of metformin in patients with poorly controlled, insulin- treated type 2 diabetes mellitus: a randomized, doubleblind, placebo-controlled trial// Ann Intern Med.-1999.-№ 131.-P.182−188.
- Bailey CJ. Metformin an update // Gen Pharmacol. — 1993. — vol.24. -P.1299 — 309.
- Bailey C.J., Turner R.C. Metformin // N.Eng.J.Med. 1996. — vol.334. -P.574 -9.
- Bailey C.J. Metformin: a useful adjunct to insulin therapy? // Diabet Med.-2000. № 17(1) -P.83−4.
- Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability European Group for the study of insulin resistance (EGIR) // Drugs. 1999. — № 58 — P.5−7.
- Benzi L., Trishitta V., Ciccarone A. Improvement with metformin in insulin internalization and processing in monocytes from NIDDM patients// Diabetes. -1990.-vol. 39.-P. 844−849.
- Biesenbach G., Rami A., Alsaraji N. Weight gain and insulin requirement in type 2 diabetic patients during the first year after initiating insulin therapy dependent on baseline BMI // Diabetes Obes Metab.- 2006.-№ 8(6).- P.669−73.
- Boggs W. Hypoglycemia more common with sulfonylurea than with metformin use//Diabetes Care. 2008. — № 31. — P.2086−2091.
- Campbell I.W., Howlett H.C. Diabetes// Metab Rev.-1995. № 1 l (Suppl 1).-P.57−62
- Carlson M. G., Campbell P. J. Intensive insulin therapy and weight gain in IDDM//Diabetes. 1993. — № 42. — P. 1700−1707.
- Carsen S.M., Rossvol O. Metformin improves blood lipid pattern in non -diabetic patients with coronary heart disease // J. Intern Med. 1996. — vol.239. -P.227 — 33.
- Chaudhury A., Tomar R., Mohanty P. The combination of insulin and metformin in treatment of non — insulin dependent diabetes mellitus Endocr Pract. — 1998, — № 4(5).- P.259 — 67.
- Clarke B. F., Campbell I.W. Comparison of metformin and chlorpropamide in non obese, maturity — onset diabetics uncontrolled on diet // Br.Med.J. — 1977. -vol. 17, N2.-P. 1576−8.
- Colwell J.A. Is it time to introduce metformin in the U. S. Diabetes Care. -1993.-vol.16-P.653−5.
- Cuyton A.C. Textbook of Medical Physiology. W.B. Saunders Co 7th Edition, 1986.
- De Fronzo R.A., Goodman A. Combined metformin/ gliburide treatment in NIDDM patients not optimally responding to maximum dose sulfonylurea: results of a multicenter trial// Diabetes. 1993. — vol.42, Suppl.I. -P.146.
- De Fronzo R.A., Goodman A. M. The Metformin Investigator Group: Efficacy of metformin in patients with non-insulin dependent diabetes mellitus// N Engl J Med.- 1995. -№ 333. -P.541−49.
- De Jager J., Kooy A. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetesmellitus: a randomized, placebo-controlled trial// J Intern Med.- 2005. № 257(1). -P.100 — 9.
- Douek I.F., Allen S.E., Ewings P. Continuing metformin when starting insulin in patients with type 2 diabetes: a double blind randomized placebo -controlled trial// Diabet Met. — 2005. — № 22 (5). — P.634 — 40.
- Dunican K.C., Desilets A.R., Montalbano J.K. Pharmacotherapy options for overweight adolescents // Ann Pharmacother. 2007. — № 41(19)-P.1445−1455.
- Duseja A., Das A., Dhiman R.K. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions // Ann Hepatol. 2007.-№ 6(4).- P. 222−226.
- Eschwege E., Richard J.L., Thibult N. Coronary disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later // Horm Metab Res.- 1985. -15 (Suppl). P. 41−46.
- Eskesen S., Kelsberg G. Clinical inquires. What is the role of combination therapy (insulin plus oral medication) in type 2 diabetes? // J Fam Pract.-2006.-№ 55(11).-P.1001−1003.
- Feinglos M.N., Thacker C.R., Lobaugh B. Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus// Diabetes Res Clin Pract. 1998. — № 39 — P. 193−199.
- Foss M.T. et al. Metformin as a cause of late-onset chronic diarrhea//Pharmacotherapy. -2001. -№ 21 (11). -P.1422−1424.
- Fritsche A., Stumvoll M. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients //Acta Diabetol.- 2000.- 37(1).-P.13−18.
- Fruewald-Schultes B., Werner K., Kerstin M. Metformin does not adversely affect hormonal and Symptomatic Responses to recurrenthypoglycemia//Journal of clinical Endocrinology&Metabolism. 2001. -№ 86(9).-P.4187−4192.
- Garvey W.T., Olefsky J. M., Griffin J. The effects of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus//Diabetes. 1985. -№ 34. — P.222−234.
- Geiss L., Herman W., Smith P. National Diabetes Data Group. Diabetes in America. Bethesda//National Institutes of Health. 1995. — P. 233−257.
- Giugliano D., De Rosa N, Di Maro G. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women // Diabetes Care.- 1993.-№ 16-P.1387−90.
- Giugliano D., Quatraro A. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors// Eur J Clin Pharmacol. 1993. — № 44. — P. 107−112.
- Global Guidelines for type 2 diabetes//International Diabetes Federation, 2005.-P.1−79.
- Grant P.J., Stickland M.H., Booth N.A. Metformin causes reduction in basal and post venous occlusion plasminogen activator inhibitor — 1 in type 2 diabetic patients // Diabetic Med. — 1991. — vol.8. — P. 361 — 5.
- Grant P.J. Beneficial effects of metformin on haemostasis and vascular function in man// Diabetes Metab. 2003. -№ 29. — P.44−52.
- Groop L.C., Kankuri M., Schalin-Jantti C. Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus // N. Engl. J. Med. 1993. — vol.328. — P. 10−4.
- Grundy S.M., Benjamin I.J., Burke G.L. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association// Circulation. 1999. — vol. 100. — P. 1134−1146.
- Gudmundsdottir H., Aksnes H. Metformin and antihypertensive therapy with drugs blocking the rennin angiotensin system, a cause of concern?// Clin Nephrol.- 2006.- № 66(5).-P.380−5.
- Hennige A.M., Ozcan U., Okada T. Alterations in growth and apop- tosis of insulin receptor substrate-1-deficient P-cells// Am. J. Physiol. Endocrinol. Metab.-2005.-№ 289.-P.337−346.
- Hermann L.S., Schersten B., Bitzen P.-O. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations//Diabetes Care. -1994. № 17. — C. 100−9.
- Hermann L.S., Katzman P., Lager I. Long term glycaemic improvement after addition of metformin to insulin in insulin — treated obese type 2 diabetes patients // Diabetes Obes Metab. — 2001.- № 3(6).- P.428 — 34.
- Hirsch I.B., Bergenstal R.M., Parkin C.G. A real-world approach to insulin therapy in primary care practice // Clin Diabetes. 2005. -№ 23. -P.78−86.
- Hollenbeck C.B., Johnson P., Varasten B.B. Effects of Metformin on glucose, insulin and lipid metabolism in patients with NIDDM by glucose tolerance test criteria// Diabete&Metabolisme. 1991. — vol.17. — P.483 — 489.
- Holstein A., Egberts E.H. Traditional contraindications to the use of metformin more harmful than beneficial? // Dtsch Med Wochenschr. -2006. -№ 131(3).-P.105−110.
- Hundal H.S., Ramlal T., Reyes R. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 mucsle cells//Endocrinology. -1992. № 131. — P. l 165−73.
- Hundal R.S., Krssak M., Deform S. Mechanism by which metformin reduces glucose production in type 2 diabetes//Diabetes Care. -1998. -№ 21. -P.1462−1469.
- Isnard F. Insulin sparing and metabolic control with metformin-insulin combination//Journ Annu Diabetol Hotel Dieu. -1997. P.305−25.
- Jaber L.A., Nowak S.N. Insulin metformin combination therapy in obese patients with type 2 diabetes // J Clin Pharmacol.- 2002.-№ 42(l).- P.89 — 94.
- Janka H.U. Platelet and endothelial function tests during metformin treatment in diabetes mellitus // Horm. Metab.Res.Suppi 1985. — Vol.15. — P. 120 -122.
- Johnson P., Sheu W.H.H., Hollenbeck C.B. Effect of Metformin on carbohydrate and lipoprotein metabolism in NIDDM patients // Diabetes Care. — 1990. -vol.13.- № 1-P.l- 8.
- Johnson J.L., Wolf S.L., Kabadi U.M. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials // Arch Intern Med.-1996. № 156. — P.259−264.
- Johnson M., Krosnick A., Carson P. A retrospective chart review of uncontrolled use of metformin as an add on therapy in type 2 diabetes // Clin Ther. — 1998. — № 20(4). -P. 691−8.
- Jungermann K., Mohler H. Bioshemie. Springer. Berlin-Heidelberg, 1980.
- Kamber N., Davis W.A., Bruce D.G., Davis T.M. Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study // Med J Aust.- 2008. № 188(8). — P.446−9.
- King H., Aubert R.E. Herman W.H. Global burden of diabetes, 1995−2025. Prevalence, numerical estimates and projections // Diabetes Care. 1998. -Vol. 2. — P.1414−41.
- Klip A., Lawrence A. Cellular mechanism of action of Metformin // Diabetes care. 1990. — Vol. 13.№ 6. — P. 696 — 704.
- Klip A, Guma A., Ramlal T. Stimulation of hexose transport by metformin in L6 muscle cells in culture // Endocrinology. -1992. -№ 130. -P. 2535−44.
- Komori T., Hotta N., Kobayashi M. Biguanides may produce hypoglycemic action in isolated rat hepatocytes through their effects on L-alanine transport // Diabetes Res Clin Pract-1993.-№ 22 P. l 1−17.
- Kozka I.J., Holman G.D. Metformin blocks down-regulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes// Diabetes.-1993.- № 42 P.1159−65.
- Kumar N., Dey C.S. Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells // Br J Pharmacol.- 2002.- № 137(3).- P.329−36.
- Lam T., Carpentier A., Lewis G.F. Mechanisms of the free fatty acid-induced increase in hepatic glucose production //Am J Physiol Endocrinol Metab.-2003.-№ 284,-P.863−873.
- Landin K., Tengborn L., Smith U. Metformin and metoprolol CR treatment in non-obese men//J Intern Med-1994. -№ 235. -P.335−41.
- Landin K., Tengborn L. Smith Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemuc, euglycemic clamp in man // Thromb Haemost. 1994. -№ 71. p.783−7.
- Lebovitz H.E., Austin M.M., Blonde L. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations // Endocr Pract.-2006.- № 12 (Suppl. 1) P.6−12.
- Lingvay I., Raskin P., Szczepaniak L.S. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes// Diabetes Complications. 2007. -№ 21 (3). -P. 137−42.
- Lin H.Y., Chung C.Y., Wang M.L. Hyperhomocysteinemia, deep vein thrombosis and vitamin B12 deficiency in a metformin-treated diabetic patient// J Formos Med Assoc. 2007. -№ 106 (9). P.774−8.
- Majithiya J.B., Balaraman R. Metformin reduces blood pressure and restores endothelial function in aorte of streptozotocin-induced diabetic rats // Life Sci.-2006. № 78(22). — P.2615−24.
- Makimattila S., Nikkila, K., Yki-Harvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus//Diabetologia. 1999. — № 42. — P.406−412.
- Matthaei S., Greten H. Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane// DiabeteMetab.-1991.-№ 17 Suppl. 1. -P. 150−158.
- Marfella R., Acampora R., Verazzo G. Metformin improves hemodynamic and rheological responses to L’arginine in NIDDM patients// Diabetes care. — 1996. Vol. 19№ 9. — P. 934 — 9.
- Meaney E., Vela A., Samaniego V. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: The Mefisto Study // Clin Exp Pharmacol Physiol.- 2008. -№ 12. P.121−25.
- Morin Papunen L., Rautio K. Metformin reduces serum C — reactive proteine levels in women with polycystic ovary syndrome // The Journal of Clinical endicrinologe and metabolism. — 2003. -P. 4649 — 4654.
- Mourao-Junior C. A, Sa J.R., Guedes O.M. Effects of metformin-on the glycemic control, lipid profile and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin// Braz J Med Biol Res.- 2006. -№ 39 (4). -P.489−94.
- Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Bavenholm P. et al. Metformin increases AMP activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes// Diabetes. — 2002. -№ 51 (7). — P. 2074 — 81.
- Nagi D.K., Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups// Diabetes Care. 1993. — № 16. — P.621−29.
- Nathan D.M., Buse J.B., Davidson M.B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy// Diabetes Care. 2006. — № 29. — P.1963−1972.
- Nathan D. M. Management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (ADA-EASD) // Diabetologia. 2008. — № 51. — P.8−11.
- Ohira M., Miyashita Y. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients// Diabetes Res Clin Pract.- 2007. № 78 (1). — P.34−41.
- Orban J.C., Ghaddab A., Chatti O. Metformin-associated lactic acidosis// Ann Fr Anaest Reanim. -2006. № 25 (10). — P. 1046−52.
- Philis-Tsimikas A., Charpentier G., Clauson P. Comparison of ince-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes// Clin. Ther. 2006. — № 28. — P. 1569−1581.
- Ponssen H.H., Elte J.W. Combined metformin and insulin therapy for patients with patients with type 2 diabetes mellitus// Clin Ther. -2000. № 22 (6). -P. 709−18.
- Prager R., Shernthaner G., Graf H. Effect of metformin on peripheral inulin sensitivity in non insulin dependent diabetes mellitus// Diabete Metab. 1986. -Vol.12N6.-P.346−50.
- Pyorala K., Savolainen E., Kaukola S. et al. Plasma insulin as coronary heart disease risk factor// Acta Med Scand.- 1985. -№ 701 (Suppl.). -P.38−52.
- Ramsdell J.W., Grossman J.A., Stephens J.M. A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose// Am J Manag Care.- 1999.-№ 5.-P. 1007−24.
- Raskin P. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes// Diabetes Metab Res Rev.- 2008. -№ 24(1).-P.3−13.
- Reaven G.M. Role of insulin resistance in human disease// Diabetes. -1998. -№ 37. -P.1595−606.
- Relimpio F., Pumar A., Losada F. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus: an open-label randomized trial// Diabet Med.-1998. № 15 (12).- P.997−1002.
- Roberts F., Ryan D.J. The safety of metformin in heart failure// Ann Pharmacother. 2007. — № 41 (4). — P.642−6.
- Robinson A.C., Burke J., Robinson S. The effects of metformin on glycemic control and serum lipids in insulin treated NIDDM patients with suboptimalmetabolic control // Diabetes Care. -1998. — № 21. -P.701 — 705.
- Rodier M., Colette C., Gouzes C. Effects of insulin therapy upon plasma lipids fatty-acids and platelet aggregation in NIDDM with secondary failure to oral antidiabetic agents // Diabetes Research and Clinical Practice. 1995. — vol.28 Iss.l.-P. 19−28.
- Russell-Jones D., Khan R., Insulin-associated weight gain in diabetes -causes, effects and coping strategies//Diabetes Obes Metab. 2007. — № 9-P.799−812.
- Ryan E.A., Imes S., Wallace C. Short-term intensive insulin therapy in newly diagnosed Type 2 diabetes// Diabetes Care.-2004.-27.-P. 1028−1032.
- Saenz A., Fernandez-Esteban I., Mataix A. Cochrane Database Syst Rev., 2005.
- Salpeter S., Greyber E., Pasternak G. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus // Cochrane Database Syst Rev.- 2006. -№ 25 (1) P.2967.
- Sarabia V, Lam L, Burdett E. Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin // J Clin Invest. 1992. -№ 90.-P. 1386−95.
- Scarpello J.H.B. Optimal dosing strategies for maximizing the clinical response to metformin in type 2 diabetes // Br J Diabetes Vase Dis.-2001.-№ 1.-P.28−36.
- Schafer G. Biguanides a review of history, pharmacodynamics and therapy // Diabete&Metabolisme (Paris). — 1983. — Vol.9. — P. 148 — 65.
- Schneider J., Erren T. Metformin — induced changes in serum lipids, lipoproteins, and apoproteins in non insulin — dependent diabetes mellitus // Aterosclerosis. — 1990. — Vol.82 N1−2. -P.97 — 103.
- Schurman L., McCarthy A.D., Sedlinsky C. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells // Clin Endocrinol Diabetes.-2008.-№ 105.-P. 181−98.
- Shaw J.S., Wilmot R.L., Kilpatrick E.S. Establishing pragmatic estimated DFR thresholds to guide metformin prescribing // Diabet Med. 2007. — № 24(10). -P.l160−3.
- Shulman G.I. Cellular mechanisms of insulin resistance// J Clin Invest.2000. -№ 106 -P.171−176.
- Signore A., Fiore V., Chianelli M. The effect of Metformin on Liver Blood-Flow in Vivo in Normal Subjects with Non-Insulin Dependent Diabetes// Diabetes Research and clinical practice. 1996. — Vol. 33. Iss2. -P.83−87.
- Skrha J., Kvasnicka J, Zima T. Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus// Eur J Clin Pharmacol. 2007. -№ 63(12).-P.l 107−1114.
- Stamler J., Vaccaro O., Neaton J. D, Wentworth D. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial//Diabetes Care. 1993. -vol.16- P. 434−44.
- Stratton I.M., Adler A.I., Neil H.A. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study// BMJ. -2000. -№ 321. -P.405−412.
- Strowing S.M., Aviles Santa M. L., Raskin P. et al. Comparison of insulinotherapy and combination therapy with insulin ahd metformin or insulin and troglitazone in type 2 diabetes// Diabetes Care. -2002. -№ 25. -P. 1691 — 1698.
- Stumvoll M., Nurhijan N. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus//N. Engl J Med.-1995.-№ 333.- P.550−54.
- Ting R.Z., Szeto C.C. Risk factors of vitamin B12 deficiency in patients receiving metformin //Arch Intern Med.-2006. № 166 (18). -P. 1975−9.
- Tokar J.L., Berg C.L. Therapeutic options in Nonalcoholic Fatty liver disease// Curr Treat Options Gastroenterol. -2002. -№ 5 (6). -P.425−436.
- Tong P.C., Chow C.C., Jorggensen L.N. The contribution of metformin to glycaemic control in patients with type 2 diabetes mellitus receiving combination therapy with insulin // Diabetes Res Clin Pract. -2002. -№ 57 (2). -P.93−8.
- Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling // Circ Res.- 2007. № 100(3).-P.328−41.
- Trischitta V., Italia S., Mazzarino S. Comparison of combined therapies in treatment of secondary failure to gliburide// Diabetes care. 1992. — Vol.15. -P.539 — 42.
- Tseng Y.H., Ueki K., Kriauciunas K.M., Kahn C.R. Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin// J. Biol. Chem.-2002. № 277. — P. 31 601−31 611.
- UKPDS 28: A randomized Trial of Efficaly of Early Addition of Metformin in Sulphonylurea-Treated Type 2 Diabetes // Diab. Care. 1998. — Vol. 21.-P. 87−92.
- UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. 1998. -Vol. 353. — P. 837−853.
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes// Br. Med. J. 1998. -Vol. 317. -P. 703−713.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with metformin compared with conventional treatment and risk ofcomplications in patients with type 2 diabetes (UKPDS 33) // Lancet. 1998. -Vol. 353. — P.837−853.
- UKPDS Group. Effect of intensive blood-glucose control with metformine on complications in overweight patients with type 2 diabetes (UKPDS34) // Lancet. 1998. — Vol. 352. — P.854−865.
- UKPDS Group. Glycaemic control with diet, sulfonnylureas, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) // JAMA. 1999. — Vol. 281. — P.2005−2012.
- UKPDS Group. UK Prospective Diabetes Study 17: a nine-year update of randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus// Ann. Intern. Med. -1996.-Vol. 124.-P.136−145.
- Vanamo R. Metformin as adjuvant to insulin therapy in type 2 diabetic patients//Diabetes Care. -1999. -№ 22(3). P.528.
- Vitale C., Mercers G., Cornoldi A. et al. Metformin improves endothelial function in patients with metabolic syndrome// J. Intern Med.- 2005- № 258(3) -P. 250−6.
- Wiernsperger N.F., Bailey C.J. // Drugs. 1999. — № 58 (Suppl.). — P.31−39.
- Wilson J.D., Foster D.W. Williams Textbook of endocrinology.-W. B. Saunders Co 7th Edition, 1985.
- Wollen N., Bailey C J. Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin// Biochem Pharmacol.- 1988.-№ 37(22).-P.4353−8.
- Wulffele M. G., Kooy A., Lehert Ph. Combination of insulin and metformin in the treatment of type 2 diabetes // Diabetes Care. 2002. — № 25. — P.2133 -2140.
- Yilmaz H., Gursoy A. Comparison of insulin monotherapy and combination therapy with insulin and metformin and rosiglitazone or insulin and acarbose in type 2 diabetes// Acta Diabetol.- 2007.-№ 44(4).-P. 187−92.
- Yki Jarvinen H. Combination therapies with insulin in type 2 diabetes// Diabetes Care. — 2001. — № 24. — P.758 — 767.
- Yki-Jarvinen H., Ryysy L., Nikkila K. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial// Ann Intern Med.-1999. -№ 130.- P. 389−396.
- Zhavez-Tapia N.C. Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systemic review// World J Gastroenterol.-2006.-№ 28.-№ 12 (48).-P.7826−31.
- Zhou G., Myers R., Li Y. Role of AMP-activated protein kinase in mechanism of metformin action//J Clin Invest. -2001. № 108(8). — P. l 167−74.
- Zou M.H., Wu Y. AMP-activated proteine kinase activation as a strategy for protecting vascular endothelial function // Clin Exp Pharmacol Physiol.- 2008. -№ 35 (5−6). P.535−45.